Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2010

01-03-2010 | Meeting Highlights

Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management

Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Authors: Steven Grunberg, Rebecca A. Clark-Snow, Jim Koeller

Published in: Supportive Care in Cancer | Special Issue 1/2010

Login to get access

Abstract

Introduction

Chemotherapy-induced nausea and vomiting remains a significant problem for cancer patients.

Discussion

Patient factors such as polypharmacy, medication costs, mucositis, and depression may hinder good antiemetic control, while high workloads, poor communication, and underestimation of the problem on the part of healthcare professionals also play a role. Improving outcomes requires accurate assessment of risk factors, use of guidelines, and better adherence to antiemetic regimens.

Conclusion

Extended-release formulations and new delivery systems such as transdermal patches, nasal sprays, and pumps provide a new strategy that may improve patient outcomes.
Appendix
Available only for authorised users
Literature
1.
Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117–121CrossRefPubMed
2.
Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schraq D (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25:5374–5380CrossRefPubMed
3.
Briesacher BA, Gurwitz JH, Soumerai SB (2007) Patients at-risk for cost-related medication nonadherence: a review of the literature. Gen Intern Med 22:864–871CrossRef
4.
Butow PN, Dunn SM, Tattersall MH, Jones QJ (1995) Computer-based interaction analysis of the cancer consultation. Br J Cancer 71:1115–1121PubMed
5.
Cervený P, Bortlik M, Kubena A, Vicek J, Lakatos PL, Lukás M (2007) Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 13:1244–1249CrossRefPubMed
6.
Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMed
7.
de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, van Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061PubMed
8.
DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 160:2101–2107CrossRefPubMed
9.
Dix SP, Cord MK, Howard SJ, Coon JL, Belt RJ, Geller RB (1999) Safety and efficacy of a continuous infusion, patient controlled antiemetic pump to facilitate outpatient administration of high-dose chemotherapy. Bone Marrow Transplant 24:561–566CrossRefPubMed
10.
Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13:112–116CrossRefPubMed
11.
Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293–1300CrossRefPubMed
12.
Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 98:2473–2482CrossRefPubMed
13.
Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, Karlsen J, Giunchedi P (2006) Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 307:9–15CrossRefPubMed
14.
Gill D, Howell J (2008) Pharmacokinetics and bioavailability of transdermal granisetron after a 6-day application of three patch sizes, compared to 2 mg once-daily oral dose of granisetron for 5 days. Abstracts of the 2008 International MASCC/ISOO Symposium held in Houston, Texas, June 26-28, 2008. Abstract 01-006
15.
Gorard DA (2006) Escalating polypharmacy. Q J Med 99:797–800
16.
Gralla RJ, Itri L, Pisko SE, Squillante AE, Kelsen DP, Braun DW Jr, Bordin LA, Braun TJ, Young CW (1981) Antiemetic efficacy of high-dose metrocloramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N Engl J Med 305:905–909PubMedCrossRef
17.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 12:2971–2994
18.
Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268CrossRefPubMed
19.
Grunberg SM, Gabrial N, Clark G (2007) Phase III trial of transdermal granisetron patch (Sancuso) compared to oral granisetron (OG) for chemotherapy-induced nausea and vomiting (CINV) after multi-day moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy. Abstracts of the 2007 International MASCC/ISOO Symposium held in St. Gallen, Switzerland, June 27–30, 2007. Abstract P-18.
20.
Herrstedt J (2004) Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 3:231–248CrossRefPubMed
21.
Herrstedt J, Aapro MS, Smuth JF, Del Favero A (1998) Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6:204–214CrossRefPubMed
22.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study. J Clin Oncol 21:4112–4119CrossRefPubMed
23.
Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M (2004) Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Soc Sci Med 59:1307–1313CrossRefPubMed
24.
Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526–536CrossRefPubMed
25.
Jones E, Koyama T, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H (2007) Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer 48:330–332CrossRefPubMed
26.
Jordan K, Sippel C, Schmoll H-J (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143–1150CrossRefPubMed
27.
Kaufman DW, Kelly P, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337–344CrossRefPubMed
28.
Kimbell JS, Segal RA, Asgharian B, Wong BA, Schroeter JD, Southall JP, Dickens CJ, Brace G, Miller FJ (2007) Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med 20:59–74CrossRefPubMed
29.
Klocker N, Hanschke W, Toussaint S, Verse T (2001) Scopolamine nasal spray in motion sickness: a randomized, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci 13:227–232CrossRefPubMed
30.
Liau CT, Chu N-M, Liu H-E, Dueson R, Lien J, Chen J-S (2005) Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes. Support Care Cancer 13:277–286CrossRefPubMed
31.
Mardby A-C, Akerlind I, Jorgensen T (2007) Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns 69:158–164PubMed
32.
Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega M (1990) The natural course of emesis after carboplatin treatment. Acta Oncol 29:593–595CrossRefPubMed
33.
McInnes FJ, O’Mahony B, Lindsay B, Band J, Wilson CG, Hodges LA, Stevens HN (2007) Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scinitigraphy. Eur J Pharm Sci 31:25–31CrossRefPubMed
34.
Morrow DG, Weiner M, Steinley D, Young J, Murray MD (2007) Patients’ health literacy and experience with instructions influence preferences for heart failure medication instructions. J Aging Health 19:575–593CrossRefPubMed
35.
Murphy BA (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5:13–21PubMed
36.
Newman SP, Steed KP, Hardy JG, Wilding IR, Hooper G, Sparrow RA (1994) The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques. J Pharm Pharmacol 46:657–660PubMed
37.
Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan–Kettering Cancer Center. J Clin Oncol 16:771–778PubMed
38.
Anonymous (2007) Oral mucosistis due to cancer treatments. La Revue Prescrire 27:286-288
39.
Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307–313CrossRefPubMed
40.
Pagano IS, Gotay CG (2005) Ethnic differential item functioning in the assessment of quality of life in cancer patients. Health Qual Life Outcomes 3:60CrossRefPubMed
41.
Penn RD, Kroin JS (1987) Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 66:181–185CrossRefPubMed
42.
Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monographs 32:32–39CrossRefPubMed
43.
Pirl WF, Temel JS, Billings A, Dahlin C, Jackson V, Prigerson HG, Greer J, Lynch TJ (2008) Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study. Psychosomatics 49:218–224CrossRefPubMed
44.
Pollak KI, Arnold RM, Jeffreys AS, Alexander SC, Olsen MK, Abernethy AP, Sugg Skinner C, Rodriguez KL, Tulsky JA (2007) Oncologist communication about emotion during visits with patients with advanced cancer. J Clin Oncol 25:5748–5752CrossRefPubMed
45.
Repetto L (2003) Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1(suppl 2):18–24PubMed
46.
Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology 21:946–953PubMed
47.
Shih Y-CT XuY, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678–685CrossRef
48.
Taylor JA, Winter L, Geyer LJ, Hawkins DS (2006) Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer 107:1400–1406CrossRefPubMed
49.
Valle AE, Wisniewski T, Isabel J, Vadillo F, Burke TA, Martinez Corona M (2006) Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. Curr Med Res Opin 22:2403–2410CrossRef
50.
Wengstrom Y, Haggmark C (1998) Assessing nursing problems of importance for the development of nursing care in a radiation therapy department. Cancer Nurs 21:50–56CrossRefPubMed
51.
White PF, Tang J, Song D, Coleman JE, Wender RH, Oqunnaiike B, Sloninsky A, Kapu R, Shah M, Webb T (2007) Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. Anesth Analg 104:92–96CrossRefPubMed
52.
53.
Winkeljohn DL (2007) Oral chemotherapy medications: the need for a nurse’s touch. Clin J Oncol Nurs 11:793–796CrossRefPubMed
54.
Woo JS (2006) Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. Arch Pharm Res 30:778–784CrossRef
55.
Zaki NM, Mortada ND, Awad GAS, Abd ElHady SS (2006) Rapid-onset intranasal delivery of metoclopramide hydrochloride part II: safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm 327:97–103CrossRefPubMed
56.
Zarowitz BJ (2007) Fixed-dose combinations for improving medication adherence in assisted living environments. Geriatr Nurs 28:341–345CrossRefPubMed
Metadata
Title
Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management
Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Authors
Steven Grunberg
Rebecca A. Clark-Snow
Jim Koeller
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue Special Issue 1/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0807-z
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits